NCT01434069View on ClinicalTrials.gov

Phase I Trial of Combination of FOLFIRI and SOM 230

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions
Gastrointestinal Tumor
Interventions
DRUG

SOM230C LAR

Participants will be given one LAR dose injected into the muscle of the buttocks by a study nurse about once every 28 days until unacceptable toxicity or progression of the disease.

DRUG

FOLFIRI Infusion

Standard therapy of FOLFIRI

Trial Locations (1)

33612

H. Lee Moffitt Cancer Center and Research Institute, Tampa

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER